{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-020494","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.682216+00:00","generated_at":"2026-05-15T23:48:29.294723+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Structure Therapeutics posts Q4 net income; aleniglipron up to 15.3% weight loss in Phase 2","bullets":["Q4 2025 net income $33.0M vs. net loss of $36.5M in Q4 2024; full-year net loss $141.2M.","Cash, equivalents and investments $1.4B as of Dec 31, 2025, funding through end of 2028.","Aleniglipron Phase 2 ACCESS II: placebo-adjusted weight loss up to 15.3% with 240 mg at 36 weeks.","Phase 3 for aleniglipron expected in H2 2026; topline 44-week data from ACCESS II due Q1 2026.","Oral amylin agonists: ACCG-2671 in Phase 1; ACCG-3535 to enter Phase 1 in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-020494","json":"https://secwatch.observer/filing/0001104659-26-020494.json","markdown":"https://secwatch.observer/filing/0001104659-26-020494.md","text":"https://secwatch.observer/filing/0001104659-26-020494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926020494/0001104659-26-020494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926020494/tm267321d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:48:29.294723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}